Alphabet Inc.’s fourth-quarter earnings report is expected to show significant growth, driven by the company’s artificial intelligence (AI) advancements. Analysts estimate revenues of $96.7 billion and net income of $26.2 billion, with earnings per share projected at $2.13.
Google’s latest AI model, Gemini 2.0, has made headlines for its capabilities in native image and audio output, enabling the development of more advanced AI agents that can complete complex tasks autonomously. This technology is expected to enhance Google’s AI Overviews feature, which reaches one billion people, allowing it to solve sophisticated queries like mathematical equations and multimodal questions.
Meanwhile, Demis Hassabis, founder of Alphabet’s drug discovery subsidiary Isomorphic Labs, announced plans to launch AI-designed drugs in clinical trials by the end of the year. This move is part of a broader effort to apply AI to science, as Hassabis noted during a panel at the World Economic Forum. Isomorphic Labs has already secured deals with Eli Lilly & Co. and Novartis to work on drug research using its AlphaFold AI model.
The upcoming earnings report will likely showcase Alphabet’s continued commitment to innovation and its potential to drive significant growth in the coming quarters.
Source: https://qz.com/google-alphabet-q4-2024-earnings-ai-gemini-1851752953